{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:31:21Z","timestamp":1793363481736,"version":"4.5.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T00:00:00Z","timestamp":1792972800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jconrel.2026.115461","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:58:25Z","timestamp":1792162705000},"page":"115461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"PA","title":["Biopharmaceutics modelling of extended-release formulations with sequential TIM-1\/TIM-2 biorelevant upper GI and colonic dissolution"],"prefix":"10.1016","volume":"400","author":[{"given":"Connor","family":"O'Farrell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maitrayee","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieke W.J.","family":"van den Elsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00e2nia Martins","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Barnhill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115461_bb0005","series-title":"IVIVC for Extended Release Hydrophilic Matrix Tablets in Consideration of Biorelevant Mechanical Stress","volume":"37(227)","author":"Mohylyuk","year":"2020"},{"key":"10.1016\/j.jconrel.2026.115461_bb0010","series-title":"Release Characteristics of Quetiapine Fumarate Extended Release Tablets Under Biorelevant Stress Test Conditions","first-page":"230","author":"Garbacz","year":"2014"},{"key":"10.1016\/j.jconrel.2026.115461_bb0015","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3390\/pharmaceutics14020291","article-title":"In vitro methodologies for evaluating colon-targeted pharmaceutical products and industry perspectives for their applications","volume":"14","author":"Garc\u00eda","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115461_bb0020","first-page":"2065","article-title":"Physiologically based biopharmaceutics modeling (PBBM): best practices for drug product quality, regulatory and industry perspectives: 2023 workshop summary report","author":"Heimbach","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115461_bb0025","doi-asserted-by":"crossref","first-page":"6272","DOI":"10.1021\/acs.molpharmaceut.3c00683","article-title":"Approaches to account for colon absorption in physiologically based biopharmaceutics modeling of extended-release drug products","author":"Jadhav","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115461_bb0030","series-title":"General Chapter <711> Dissolution","author":"United States Pharmacopeia","year":"2011"},{"key":"10.1016\/j.jconrel.2026.115461_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113924","article-title":"In vitro models to evaluate ingestible devices: present status and current trends","volume":"178","author":"O'Farrell","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115461_bb0040","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.5c00910","article-title":"Leveraging biopharmaceutics bridging risk assessment and in vivo predictive tools to accelerate immediate release drug product development by minimized need for clinical bridging studies","volume":"22","author":"Engman","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115461_bb0045","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.5c01197","article-title":"An expert's view on the application of TIM technology in the development of oral drug products","author":"L\u00f3pez M\u00e1rmol","year":"2026","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.115461_bb0050","series-title":"Assessment Report: Litfulo (Ritlecitinib)","author":"European Medicines Agency","year":"2023"},{"key":"10.1016\/j.jconrel.2026.115461_bb0055","series-title":"TIM-1 and Tiny-TIM as Robust In Vitro Models for Oral Biopharmaceutics: Evidence From an International Ring Study","volume":"18(4)","author":"O'Farrell","year":"2026"},{"key":"10.1016\/j.jconrel.2026.115461_bb0060","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s11095-010-0223-6","article-title":"Iorelevant media to simulate fluids in the ascending colon of humans and their usefulness in predicting intracolonic drug solubility","author":"Vertzoni","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2026.115461_bb0065","series-title":"The TNO In Vitro Model of the Colon (TIM-2)","author":"Venema","year":"2015"},{"issue":"3","key":"10.1016\/j.jconrel.2026.115461_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15030882","article-title":"Use of in vitro dynamic colon model (DCM) to inform a physiologically based biopharmaceutic model (PBBM) to predict the in vivo performance of a modified-release formulation of theophylline","volume":"15","author":"Stamatopoulos","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.115461_bb0075","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.foodres.2016.01.030","article-title":"Development of an advanced in vitro model of the stomach and its evaluation versus human gastric physiology","author":"Bellman","year":"2016","journal-title":"Food Res. Int."},{"key":"10.1016\/j.jconrel.2026.115461_bb0080","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1136\/gut.27.8.886","article-title":"Transit of pharmaceutical dosage forms through the small intestine","volume":"27","author":"Davis","year":"1986","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2026.115461_bb0085","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijpharm.2015.11.048","article-title":"Evaluation of two dynamic in vitro models simulating fasted and fed state conditions in the upper gastrointestinal tract (TIM-1 and tiny-TIM) for investigating the bioaccessibility of pharmaceutical compounds from oral dosage forms","author":"Verwei","year":"2016","journal-title":"Int. J. Pharm."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926008655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926008655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:38:11Z","timestamp":1793360291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926008655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":17,"alternative-id":["S0168365926008655"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115461","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biopharmaceutics modelling of extended-release formulations with sequential TIM-1\/TIM-2 biorelevant upper GI and colonic dissolution","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115461","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115461"}}